Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun 18;69(1):144-146.
doi: 10.1093/cid/ciy982.

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Nicolas Salvadori  1   2 , Bo Fan  3 , Waralee Teeyasoontranon  4 , Nicole Ngo-Giang-Huong  1   2   5 , Siriluk Phanomcheong  6 , Anita Luvira  7 , Achara Puangsombat  8 , Arunrat Suwannarat  9 , Ussanee Srirompotong  10 , Chaiwat Putiyanun  11 , Tim R Cressey  1   2   5   12 , Luc Decker  1   2 , Woottichai Khamduang  2 , Linda Harrison  13 , Camlin Tierney  13 , John A Shepherd  3   14 , Athena P Kourtis  15 , Marc Bulterys  15   16 , George K Siberry  17 , Gonzague Jourdain  1   2   5
Affiliations
Clinical Trial

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Nicolas Salvadori et al. Clin Infect Dis. .

Abstract

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.

Keywords: bone mineral density; growth; hepatitis B; pregnancy; tenofovir disoproxil fumarate.

PubMed Disclaimer

References

    1. Terrault NA , Lok ASF , McMahon BJ , et al. . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560–99. - PMC - PubMed
    1. Siberry GK , Jacobson DL , Kalkwarf HJ , et al. . Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015; 61:996–1003. - PMC - PubMed
    1. Jourdain G , Ngo-Giang-Huong N , Cressey TR , et al. . Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis 2016; 16:393. - PMC - PubMed
    1. Jourdain G , Ngo-Giang-Huong N , Harrison L , et al. . Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. New Eng J Med 2018; 378:911–23. - PMC - PubMed
    1. Kalkwarf HJ , Zemel BS , Yolton K , Heubi JE. Bone mineral content and density of the lumbar spine of infants and toddlers: influence of age, sex, race, growth, and human milk feeding. J Bone Miner Res 2013; 28:206–12. - PMC - PubMed

Publication types

Associated data